Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity

International Journal of Cancer

Volumn 125, Issue 9, 2009, Pages 2173-2178

  Friedman, Gary D ^a   Jiang, Sheng Fang ^a   Udaltsova, Natalia ^a   Quesenberry Jr , Charles P ^a   Chan, James ^a   Habel, Laurel A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

Cancer; Pharmaceuticals; Pharmacoepidemiology

Indexed keywords

CHLORAMPHENICOL; CYCLOPHOSPHAMIDE; GRISEOFULVIN; IRON DEXTRAN; METRONIDAZOLE; OXAZEPAM; PHENOBARBITAL; PHENOXYBENZAMINE; PHENYTOIN; PROPYLTHIOURACIL; DRUG;

ARTICLE; CANCER REGISTRY; CANCER RESEARCH; CARCINOGENICITY; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED PRACTICE; HUMAN; LUNG CANCER; PRIORITY JOURNAL; THYROID DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; NEOPLASM;

FEMALE; HUMANS; MALE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 70249124253     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24545     Document Type: Article

References (28)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some pharmaceutical drugs, vol.24. World Health Organization, International Agency for Research on Cancer: Lyon, France, 1980.
2. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs, vols. 1-42, suppl. no.7. World Health Organization, International Agency for Research on Cancer: Lyon, France, 1987.
3. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Pharmaceutical drugs, vol.50. World Health Organization, International Agency for Research on Cancer: Lyon, France, 1990.
4. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some pharmaceutical drugs, vol.66. World Health Organization, International Agency for Research on Cancer: Lyon, France, 1996.
5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some antiviral and antineoplastic drugs and other pharmaceutical agents, vol.76. World Health Organization, International agency for Research on Cancer: Lyon, France, 2000.
6. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some thyrotropic drugs, vol.79. World Health Organization, International Agency for Research on Cancer: Lyon, France, 2001.
7. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen- progestogen menopausal therapy, vol.91. World Health Organization, International Agency for Research on Cancer: Lyon, France, 2007.
8. Habel LA, Friedman GD. Pharmaceuticals other than hormones. In: Schottenfeld D, Fraumeni JF, Jr, eds. Cancer epidemiology and prevention, 3rd edn. New York: Oxford University Press, 2006. 489-506.
9. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285: 1736-1745 (Pubitemid 32259908)
10. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007;19:446-451 (Pubitemid 47356600)
11. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-710
12. Selby JV, Smith DH, Johnson E, Raebel MA, Friedman GD, McFarland BH. The Kaiser Permanente Medical Care Program. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. New York: John Wiley & Sons Inc., 2005. 241-259
13. Oehrli MD, Quesenberry CP, Leyden W. Northern California Cancer Registry: 2006 annual report on trends, incidence, and outcomes. Kaiser Permanente, Northern California Cancer Registry: Oakland, CA; 2006.
14. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia: Lippincott, Williams and Wilkins, 2008:125.
15. SAS Institute Inc. SAS OnlineDoc® 9.1.2. Cary, NC: SAS Institute Inc., 2004.
16. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303. (Pubitemid 43797117)
17. Friedman GD. Jiang S-F, Udaltsova N, Chan J, Habel LA. Pharmaceuticals that cause mammary gland tumors in animals: findings in women. Breast Cancer Res Treat, Epub ahead of print.
18. Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc 2005;53:948-954 (Pubitemid 41647590)
19. Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 1983;71:1165-1175
20. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989;49:5736-5747
21. Van Den Eeden SK, Friedman GD. Prescription drug screening for subsequent carcinogenicity. Pharmacoepidemiol Drug Saf 1995;4: 275-287
22. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988;63:147-153
23. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979;301:519-522
24. Friedman GD. Cancer after metronidazole [Letter]. N Engl J Med 1980;302:519.
25. Friedman GD, Selby JV. Metronidazole and cancer [Letter]. JAMA 1989;261:866.
26. Bribes E, Carrière D, Goubet C, Galiègue S, Casellas P, Simony-Lafontaine J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in human tissues. J Histochem Cytochem 2004; 52:19-28.
27. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980;65:723-733 (Pubitemid 10059961)
28. Ron E, Schneider AB. Thyroid cancer. In: Schottenfeld D, Fraumeni JF, Jr, eds. Cancer epidemiology and prevention, 3rd edn. New York: Oxford University Press, 2006. 975-994